Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated just now
Peer-reviewedCC BY 4.0Frontiers in Neurology

Perioperative hydrocortisone for modulating stress and inflammation after microvascular decompression for hemifacial spasm: a single-center, randomized, assessor-blinded, controlled trial protocol

  • Renchao Yu1
  • Yinfu Xu1
  • Jing Wang2
  • Tao Liu3
  • Yuezhen Shen4
  • Jie Liu1
4 affiliations
  1. 1Department of Neurosurgery, The Second People's Hospital of Liaocheng
  2. 2Department of Oncology, The Second People's Hospital of Liaocheng
  3. 3Department of Neurosurgery, Xuanwu Hospital, Capital Medical University
  4. 4Department of Neurology, The Second People's Hospital of Liaocheng
Open at sourceDOICite

Abstract

Background: Microvascular decompression (MVD) for hemifacial spasm triggers substantial perioperative stress and inflammatory responses that may contribute to early postoperative symptoms and potentially influence long-term surgical outcomes. Perioperative corticosteroids can modulate these responses, but their efficacy and safety in this specific neurosurgical population remain inadequately characterized. This trial aims to evaluate whether short-course perioperative hydrocortisone reduces early postoperative symptom burden and to explore its effects on biomarker dynamics and long-term efficacy.

Methods: This single-center, randomized, assessor-blinded, controlled trial will enroll 100 patients aged 18–70 years undergoing elective MVD for primary hemifacial spasm. Participants will be allocated 1:1 to receive either intravenous hydrocortisone (100 mg at induction, then days 1–2) or matching placebo. Primary outcomes are mean postoperative headache intensity (visual analogue scale, days 1–3) and 72-h cumulative rescue opioid consumption (oral morphine milligram equivalents). Secondary outcomes include recovery parameters, postoperative symptoms, and inflammatory biomarkers (interleukin-6, C-reactive protein, S100B), with serum cortisol reported only as a descriptive drug exposure variable. Long-term hemifacial spasm control and quality of life at 6 months will be explored. Safety monitoring includes infection, hyperglycemia, and psychiatric symptoms through 30 days. Intention-to-treat analysis will use Bonferroni-adjusted α = 0.025 for primary outcomes.

Ethics and dissemination: The protocol has been approved by the Medical Ethics Committee of the Second People’s Hospital of Liaocheng (Approval Number: [2025] Ethical Review No. (090), date of approval: 31 December 2025). The trial was prospectively registered in the Chinese Clinical Trial Registry (ChiCTR2600117513) on 26 January 2026, and recruitment of the first participant has not yet commenced. All participants will provide written informed consent. Results will be disseminated through peer-reviewed publications and conference presentations regardless of findings.

Critical trial registration: https://www.chictr.org.cn/ , ChiCTR2600117513.

Related

  1. Retrospective study: preoperative MRI features for predicting microvascular decompression outcomes in trigeminal neuralgia.
    Fei Chen, Dandan Shang, Dengbin Sun +1
    BMC medical informatics and decision makingPeer-reviewedCC BYFull textGeneral medicineEurope PMCPMC
  2. Chronic Inflammation and Coronary Microvascular Dysfunction
    Huijing Yao, Jiangwei Cheng, Luqun Yang +2
    Reviews in cardiovascular medicinePeer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  3. Re-Du-Ning Alleviates Airway-Intestinal Inflammation of COPD Rats by Regulating Glycerophospholipid Metabolism and Modulating Gut Microbiome
    Yule Wang, Lanyu Cheng, Chunyan Wang +5
    Medical sciences (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Pimpinella brachycarpa extract attenuates periodontal inflammation by modulating the PI3K/Akt–NF-κB signaling pathway
    A. Yeong Lee, Su-Bin Park, Eunjung Son +6
    Frontiers in pharmacologyPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMC
  5. Perioperative inflammation in gynecologic oncology: nursing strategies for enhanced recovery and complication prevention
    Xiaoyan Chen, Zhongshu Zhang, Shanli Xie +3
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{yu2026perioperative,
  title = {{Perioperative hydrocortisone for modulating stress and inflammation after microvascular decompression for hemifacial spasm: a single-center, randomized, assessor-blinded, controlled trial protocol}},
  author = {Renchao Yu and Yinfu Xu and Jing Wang and Tao Liu and Yuezhen Shen and Jie Liu},
  journal = {Frontiers in Neurology},
  year = {2026},
  month = nov,
  doi = {10.3389/fneur.2026.1887029},
  url = {https://www.frontiersin.org/articles/10.3389/fneur.2026.1887029/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Perioperative hydrocortisone for modulating stress and inflammation after microvascular decompression for hemifacial spasm: a single-center, randomized, assessor-blinded, controlled trial protocol
AU  - Renchao Yu
AU  - Yinfu Xu
AU  - Jing Wang
AU  - Tao Liu
AU  - Yuezhen Shen
AU  - Jie Liu
PY  - 2026
DA  - 2026/11/02
JO  - Frontiers in Neurology
DO  - 10.3389/fneur.2026.1887029
UR  - https://www.frontiersin.org/articles/10.3389/fneur.2026.1887029/full
AB  - Background: Microvascular decompression (MVD) for hemifacial spasm triggers substantial perioperative stress and inflammatory responses that may contribute to early postoperative symptoms and potentially influence long-term surgical outcomes. Perioperative corticosteroids can modulate these responses, but their efficacy and safety in this specific neurosurgical population remain inadequately characterized. This trial aims to evaluate whether short-course perioperative hydrocortisone reduces early postoperative symptom burden and to explore its effects on biomarker dynamics and long-term efficacy.  Methods: This single-center, randomized, assessor-blinded, controlled trial will enroll 100 patients aged 18–70 years undergoing elective MVD for primary hemifacial spasm. Participants will be allocated 1:1 to receive either intravenous hydrocortisone (100 mg at induction, then days 1–2) or matching placebo. Primary outcomes are mean postoperative headache intensity (visual analogue scale, days 1–3) and 72-h cumulative rescue opioid consumption (oral morphine milligram equivalents). Secondary outcomes include recovery parameters, postoperative symptoms, and inflammatory biomarkers (interleukin-6, C-reactive protein, S100B), with serum cortisol reported only as a descriptive drug exposure variable. Long-term hemifacial spasm control and quality of life at 6 months will be explored. Safety monitoring includes infection, hyperglycemia, and psychiatric symptoms through 30 days. Intention-to-treat analysis will use Bonferroni-adjusted α = 0.025 for primary outcomes.  Ethics and dissemination: The protocol has been approved by the Medical Ethics Committee of the Second People’s Hospital of Liaocheng (Approval Number: [2025] Ethical Review No. (090), date of approval: 31 December 2025). The trial was prospectively registered in the Chinese Clinical Trial Registry (ChiCTR2600117513) on 26 January 2026, and recruitment of the first participant has not yet commenced. All participants will provide written informed consent. Results will be disseminated through peer-reviewed publications and conference presentations regardless of findings.  Critical trial registration: https://www.chictr.org.cn/ , ChiCTR2600117513.
SN  - 1664-2295
ER  -